Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.
Breast Cancer
DIETARY_SUPPLEMENT: Omega-3 Fatty Acids|OTHER: Placebo Capsule|OTHER: Diet and Exercise
Dropout rate, Measured as the number of participants that dropout before diet+intervention period is complete, Up to 6 Months
Study design feasibility, Based on eligibility criteria, study procedures and participation of subjects the study design will be measured to see if it will practically work with a larger study population, Up to 6 months|Modulation of breast cancer risk biomarkers, Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers, Change from Baseline to 6 Months|Modulation of breast cancer risk biomarkers in benign breast tissue, Measure change in fasting and postprandial blood inflammatory, and risk biomarkers, Change from Baseline to 6 Months|Modulation of breast cancer risk biomarkers, Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers, Change from Baseline to 12 Months|Modulation of breast cancer risk biomarkers in benign breast tissue, Measure change in fasting and postprandial blood inflammatory, and risk biomarkers, Change from Baseline to 12 Months|Weight gain, Measure change in weight in participants during the 6-12 month maintenance phase, Change from 6 Months to 12 Months|Change in Gut Microbiome, Change in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA):arachidonic acid (AA) ratio, Change from Baseline to Month 6
Subjects will all participate in a 6-month weight loss intervention. Subjects will be randomized to receive either blinded placebo or omega-3 fatty acids for 6 months.